AU2011346515B2 - Pharmaceutical compositions of tenecteplase - Google Patents

Pharmaceutical compositions of tenecteplase Download PDF

Info

Publication number
AU2011346515B2
AU2011346515B2 AU2011346515A AU2011346515A AU2011346515B2 AU 2011346515 B2 AU2011346515 B2 AU 2011346515B2 AU 2011346515 A AU2011346515 A AU 2011346515A AU 2011346515 A AU2011346515 A AU 2011346515A AU 2011346515 B2 AU2011346515 B2 AU 2011346515B2
Authority
AU
Australia
Prior art keywords
tnk
tenecteplase
composition
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011346515A
Other languages
English (en)
Other versions
AU2011346515A1 (en
Inventor
Pritiranjan BHANDARI
Maheshwari Kumar MISHRA
Sanjay Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gennova Biopharmaceuticals Ltd
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011346515(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of AU2011346515A1 publication Critical patent/AU2011346515A1/en
Application granted granted Critical
Publication of AU2011346515B2 publication Critical patent/AU2011346515B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2011346515A 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase Active AU2011346515B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3516/MUM/2010 2010-12-23
IN3516MU2010 2010-12-23
PCT/IN2011/000863 WO2012085933A1 (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Publications (2)

Publication Number Publication Date
AU2011346515A1 AU2011346515A1 (en) 2013-07-04
AU2011346515B2 true AU2011346515B2 (en) 2017-01-19

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011346515A Active AU2011346515B2 (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Country Status (17)

Country Link
US (2) US20130323227A1 (enExample)
EP (1) EP2654770B1 (enExample)
JP (1) JP6375112B2 (enExample)
CN (1) CN103391785A (enExample)
AU (1) AU2011346515B2 (enExample)
BR (1) BR112013015914B1 (enExample)
CO (1) CO6721059A2 (enExample)
DK (1) DK2654770T3 (enExample)
EA (1) EA026017B1 (enExample)
ES (1) ES2687850T3 (enExample)
LT (1) LT2654770T (enExample)
MX (1) MX356199B (enExample)
MY (1) MY171723A (enExample)
NZ (1) NZ611706A (enExample)
PL (1) PL2654770T3 (enExample)
PT (1) PT2654770T (enExample)
WO (1) WO2012085933A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383595B (es) * 2014-10-21 2025-03-14 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)
EP3624832B1 (en) * 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
WO2019229764A1 (en) * 2018-06-01 2019-12-05 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027687A2 (en) * 2006-08-29 2008-03-06 Genentech, Inc. Use of tenecteplase for treating acute ischemic stroke
WO2008152075A1 (en) * 2007-06-13 2008-12-18 Cmc Biologics A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
CA2668347C (en) * 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027687A2 (en) * 2006-08-29 2008-03-06 Genentech, Inc. Use of tenecteplase for treating acute ischemic stroke
WO2008152075A1 (en) * 2007-06-13 2008-12-18 Cmc Biologics A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
EA201300746A1 (ru) 2013-11-29
WO2012085933A1 (en) 2012-06-28
AU2011346515A1 (en) 2013-07-04
NZ611706A (en) 2015-04-24
MX2013007381A (es) 2013-08-29
PT2654770T (pt) 2018-10-19
EP2654770A4 (en) 2014-05-21
US20130323227A1 (en) 2013-12-05
ES2687850T3 (es) 2018-10-29
EP2654770A1 (en) 2013-10-30
JP2014502608A (ja) 2014-02-03
LT2654770T (lt) 2018-09-10
MY171723A (en) 2019-10-24
MX356199B (es) 2018-05-18
BR112013015914B1 (pt) 2021-06-08
JP6375112B2 (ja) 2018-08-15
BR112013015914A2 (pt) 2016-10-11
EA026017B1 (ru) 2017-02-28
CO6721059A2 (es) 2013-07-31
CN103391785A (zh) 2013-11-13
US9943575B2 (en) 2018-04-17
EP2654770B1 (en) 2018-07-11
US20160310580A1 (en) 2016-10-27
DK2654770T3 (en) 2018-10-29
PL2654770T3 (pl) 2018-12-31

Similar Documents

Publication Publication Date Title
DK1987141T3 (en) COMPOSITIONS SUITABLE FOR TREATING COLLAGEN-CONDUCTED DISEASES
EP0217379B1 (en) Thrombolytic composition and a process for production thereof
DE3316297A1 (de) Humangewebe-plasminogen-aktivator
US9943575B2 (en) Pharmaceutical compositions of tenecteplase
US4898826A (en) Method to solubilize tissue plasminogen activator
JPH03504327A (ja) プラスミノーゲンアクチベーターの変異体およびその製造方法
AU611932B2 (en) Novel complex
KR100508043B1 (ko) rDSPAα1의 제조방법
US5342616A (en) Method of administering tissue plasminogen activator
WO1990001333A1 (en) METHOD FOR PREPARING tPA COMPOSITIONS
CA1338551C (en) Medicament for thrombotic disorder containing t-pa
HK40122399A (en) Compositions suitable for treating collagen-mediated diseases
CA2245554C (en) Method for the production of rdspa .alpha.1
CN110016471A (zh) 重组安克洛酶及工业规模制备和纯化方法及其组合物
EP0475719A2 (en) Platelet derived growth regulating peptide

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)